Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer Harboring MET-al

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Shanghai Haihe Pharmaceutical Co., Ltd

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.